PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss

Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A. Yap, Gordon Mills, Guang Peng

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    PARP inhibitors (PARPi) have shown remarkable therapeu-way and stimulated production of type I IFNs to induce tic efficacy against BRCA1/2-mutant cancers through a syn-antitumor immunity independent of BRCAness. These effects thetic lethal interaction. PARPi exert their therapeutic effects of PARPi were further enhanced by immune checkpoint mainly through the blockade of ssDNA damage repair, which blockade. Overall, these results provide a mechanistic ratio-leads to the accumulation of toxic DNA double-strand breaks nale for using PARPi as immunomodulatory agents to harness specifically in cancer cells with DNA repair deficiency (BCRA-the therapeutic efficacy of immune checkpoint blockade. ness), including those harboring BRCA1/2 mutations. Here we show that PARPi-mediated modulation of the immune Significance: This work uncovers the mechanism behind response contributes to their therapeutic effects independently the clinical efficacy of PARPi in patients with both BRCA-of BRCA1/2 mutations. PARPi promoted accumulation of wild-type and BRCA-mutant tumors and provides a ratio-cytosolic DNA fragments because of unresolved DNA lesions, nale for combining PARPi with immunotherapy in patients which in turn activated the DNA-sensing cGAS–STING path-with cancer.

    Original languageEnglish (US)
    Pages (from-to)311-319
    Number of pages9
    JournalCancer Research
    Volume79
    Issue number2
    DOIs
    StatePublished - Jan 15 2019

    Fingerprint

    Therapeutic Uses
    Therapeutics
    DNA
    Neoplasms
    DNA Repair-Deficiency Disorders
    Tics
    Mutation
    Double-Stranded DNA Breaks
    Poly(ADP-ribose) Polymerase Inhibitors
    Poisons
    Immunotherapy
    Immunity

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss. / Shen, Jianfeng; Zhao, Wei; Ju, Zhenlin; Wang, Lulu; Peng, Yang; Labrie, Marilyne; Yap, Timothy A.; Mills, Gordon; Peng, Guang.

    In: Cancer Research, Vol. 79, No. 2, 15.01.2019, p. 311-319.

    Research output: Contribution to journalArticle

    Shen, Jianfeng ; Zhao, Wei ; Ju, Zhenlin ; Wang, Lulu ; Peng, Yang ; Labrie, Marilyne ; Yap, Timothy A. ; Mills, Gordon ; Peng, Guang. / PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss. In: Cancer Research. 2019 ; Vol. 79, No. 2. pp. 311-319.
    @article{b9cf698398114dcca239d4038140726c,
    title = "PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss",
    abstract = "PARP inhibitors (PARPi) have shown remarkable therapeu-way and stimulated production of type I IFNs to induce tic efficacy against BRCA1/2-mutant cancers through a syn-antitumor immunity independent of BRCAness. These effects thetic lethal interaction. PARPi exert their therapeutic effects of PARPi were further enhanced by immune checkpoint mainly through the blockade of ssDNA damage repair, which blockade. Overall, these results provide a mechanistic ratio-leads to the accumulation of toxic DNA double-strand breaks nale for using PARPi as immunomodulatory agents to harness specifically in cancer cells with DNA repair deficiency (BCRA-the therapeutic efficacy of immune checkpoint blockade. ness), including those harboring BRCA1/2 mutations. Here we show that PARPi-mediated modulation of the immune Significance: This work uncovers the mechanism behind response contributes to their therapeutic effects independently the clinical efficacy of PARPi in patients with both BRCA-of BRCA1/2 mutations. PARPi promoted accumulation of wild-type and BRCA-mutant tumors and provides a ratio-cytosolic DNA fragments because of unresolved DNA lesions, nale for combining PARPi with immunotherapy in patients which in turn activated the DNA-sensing cGAS–STING path-with cancer.",
    author = "Jianfeng Shen and Wei Zhao and Zhenlin Ju and Lulu Wang and Yang Peng and Marilyne Labrie and Yap, {Timothy A.} and Gordon Mills and Guang Peng",
    year = "2019",
    month = "1",
    day = "15",
    doi = "10.1158/0008-5472.CAN-18-1003",
    language = "English (US)",
    volume = "79",
    pages = "311--319",
    journal = "Journal of Cancer Research",
    issn = "0099-7013",
    publisher = "American Association for Cancer Research Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss

    AU - Shen, Jianfeng

    AU - Zhao, Wei

    AU - Ju, Zhenlin

    AU - Wang, Lulu

    AU - Peng, Yang

    AU - Labrie, Marilyne

    AU - Yap, Timothy A.

    AU - Mills, Gordon

    AU - Peng, Guang

    PY - 2019/1/15

    Y1 - 2019/1/15

    N2 - PARP inhibitors (PARPi) have shown remarkable therapeu-way and stimulated production of type I IFNs to induce tic efficacy against BRCA1/2-mutant cancers through a syn-antitumor immunity independent of BRCAness. These effects thetic lethal interaction. PARPi exert their therapeutic effects of PARPi were further enhanced by immune checkpoint mainly through the blockade of ssDNA damage repair, which blockade. Overall, these results provide a mechanistic ratio-leads to the accumulation of toxic DNA double-strand breaks nale for using PARPi as immunomodulatory agents to harness specifically in cancer cells with DNA repair deficiency (BCRA-the therapeutic efficacy of immune checkpoint blockade. ness), including those harboring BRCA1/2 mutations. Here we show that PARPi-mediated modulation of the immune Significance: This work uncovers the mechanism behind response contributes to their therapeutic effects independently the clinical efficacy of PARPi in patients with both BRCA-of BRCA1/2 mutations. PARPi promoted accumulation of wild-type and BRCA-mutant tumors and provides a ratio-cytosolic DNA fragments because of unresolved DNA lesions, nale for combining PARPi with immunotherapy in patients which in turn activated the DNA-sensing cGAS–STING path-with cancer.

    AB - PARP inhibitors (PARPi) have shown remarkable therapeu-way and stimulated production of type I IFNs to induce tic efficacy against BRCA1/2-mutant cancers through a syn-antitumor immunity independent of BRCAness. These effects thetic lethal interaction. PARPi exert their therapeutic effects of PARPi were further enhanced by immune checkpoint mainly through the blockade of ssDNA damage repair, which blockade. Overall, these results provide a mechanistic ratio-leads to the accumulation of toxic DNA double-strand breaks nale for using PARPi as immunomodulatory agents to harness specifically in cancer cells with DNA repair deficiency (BCRA-the therapeutic efficacy of immune checkpoint blockade. ness), including those harboring BRCA1/2 mutations. Here we show that PARPi-mediated modulation of the immune Significance: This work uncovers the mechanism behind response contributes to their therapeutic effects independently the clinical efficacy of PARPi in patients with both BRCA-of BRCA1/2 mutations. PARPi promoted accumulation of wild-type and BRCA-mutant tumors and provides a ratio-cytosolic DNA fragments because of unresolved DNA lesions, nale for combining PARPi with immunotherapy in patients which in turn activated the DNA-sensing cGAS–STING path-with cancer.

    UR - http://www.scopus.com/inward/record.url?scp=85059899450&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85059899450&partnerID=8YFLogxK

    U2 - 10.1158/0008-5472.CAN-18-1003

    DO - 10.1158/0008-5472.CAN-18-1003

    M3 - Article

    VL - 79

    SP - 311

    EP - 319

    JO - Journal of Cancer Research

    JF - Journal of Cancer Research

    SN - 0099-7013

    IS - 2

    ER -